Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Antimicrob Chemother ; 77(11): 3069-3076, 2022 10 28.
Article in English | MEDLINE | ID: mdl-35996887

ABSTRACT

BACKGROUND: Patients with haematological malignancies frequently endure neutropenia and gastrointestinal (GI)-mucositis after high-dose chemotherapy. In these patients, ciprofloxacin is used for Gram-negative infection prophylaxis. OBJECTIVES: We investigate ciprofloxacin pharmacokinetics after oral administration in patients with haematological malignancies and explore the impact of GI-mucositis on oral bioavailability and clearance in order to assure adequate systemic exposure. METHODS: Adult haematological patients from two Dutch University Medical Centres received 500 mg twice daily oral ciprofloxacin for Gram-negative prophylaxis. The ciprofloxacin plasma concentrations were collected at various timepoints after oral ciprofloxacin administration and at various days after completion of chemotherapy. Data obtained after oral and intravenous ciprofloxacin administration in 28 healthy volunteers without mucositis served as a control group (391 samples). For haematological patients the degree of GI-mucositis was assessed using the Daily Gut Score (DGS), plasma citrulline and albumin. Data were analysed by non-linear mixed-effects modelling. RESULTS: In total, 250 blood samples were collected in 47 patients with a wide variety of haematological malignancies between 0-30 days after start of chemotherapy. Mucositis was generally mild [DGS median (IQR) 1 (1-1) and citrulline 16 µmol/L (12-23)]. The time to Cmax was slower in haematological patients compared with healthy volunteers although no association with the degree of mucositis (defined as DGS or citrulline) could be identified. Ciprofloxacin bioavailability and clearance were 60% and 33.2 L/h, respectively. CONCLUSIONS: This study supports oral dosing of ciprofloxacin as Gram-negative infection prophylaxis in haematological patients with mild-to-moderate mucositis capable of oral intake.


Subject(s)
Hematologic Neoplasms , Mucositis , Adult , Humans , Ciprofloxacin , Mucositis/prevention & control , Mucositis/drug therapy , Biological Availability , Citrulline , Hematologic Neoplasms/complications , Hematologic Neoplasms/drug therapy , Administration, Oral
3.
Neth J Med ; 71(5): 265-9, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23799317

ABSTRACT

The differential diagnosis of chest pain in a patient with sickle cell disease is difficult and may encompass several serious conditions, including chest syndrome, pulmonary embolism and infectious complications. In this manuscript we provide an overview on the various underlying diseases that may cause chest pain in patients with sickle cell disease and provide clues for a proper diagnostic workup.


Subject(s)
Acute Chest Syndrome/etiology , Anemia, Sickle Cell/complications , Chest Pain/etiology , Myocardial Infarction/etiology , Pulmonary Embolism/etiology , Acute Chest Syndrome/diagnosis , Adult , Chest Pain/diagnosis , Coronary Angiography , Diagnosis, Differential , Disease Progression , Electrocardiography , Female , Humans , Myocardial Infarction/diagnosis , Pulmonary Embolism/diagnosis
4.
Oncogene ; 30(6): 701-13, 2011 Feb 10.
Article in English | MEDLINE | ID: mdl-20935673

ABSTRACT

In recent years considerable progress has been made in treatment strategies for chronic lymphocytic leukemia (CLL). However, the disease remains incurable because of the development of chemoresistance. Strategies to overcome resistance mechanisms are therefore highly needed. At least two mechanisms contribute to the development of resistance to drugs; acquired mutations resulting in a dysfunctional p53 response and shifts in the balance between apoptosis-regulating proteins. Platinum-based compounds have been successfully applied in relapsed lymphoma and recently also in high-risk CLL. In this study we investigated the efficacy and mechanism of action of cisplatinum (CDDP) in chemorefractory CLL. Independent of p53-functional status, CDDP acted synergistically with fludarabine (F-ara-A). The response involved generation of reactive oxygen species (ROS), which led to specific upregulation of the proapoptotic BH3-only protein Noxa. Induction of Noxa resulted in cell death by apoptosis as inhibition of caspase activation completely abrogated cell death. Furthermore, drug-resistance upon CD40-ligand stimulation, a model for the protective stimuli provided in lymph nodes, could also be overcome by CDDP/F-ara-A. ROS accumulation resulted in Noxa upregulation mainly at the transcriptional level and this was, at least in part, mediated by the mitogen-activated protein kinase p38. Finally, Noxa RNA-interference markedly decreased sensitivity to CDDP/F-ara-A, supporting a key role for Noxa as mediator between ROS signaling and apoptosis induction. Our data indicate that interference in the cellular redox balance can be exploited to overcome chemoresistance in CLL.


Subject(s)
Drug Resistance, Neoplasm , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Proto-Oncogene Proteins c-bcl-2/metabolism , Reactive Oxygen Species/metabolism , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/metabolism , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols , Apoptosis/drug effects , Apoptosis Regulatory Proteins/metabolism , CD40 Antigens/metabolism , Cisplatin/metabolism , Cisplatin/therapeutic use , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Middle Aged , Proto-Oncogene Proteins c-bcl-2/genetics , Tumor Cells, Cultured , Up-Regulation , Vidarabine/analogs & derivatives , Vidarabine/metabolism , Vidarabine/therapeutic use , p38 Mitogen-Activated Protein Kinases/metabolism
5.
Oncogene ; 29(36): 5071-82, 2010 Sep 09.
Article in English | MEDLINE | ID: mdl-20581863

ABSTRACT

Chronic lymphocytic leukemia (CLL) cells circulating in peripheral blood (PB) differ from the leukemic fraction in lymph nodes (LNs) with respect to cell division and drug sensitivity. CD40 stimulation of PB CLL cells in vitro results in chemoresistance and provides a partial model for the LN microenvironment. The TLR9 ligand CpG induces proliferation in immunoglobulin variable heavy-chain-unmutated CLL, but apoptosis in immunoglobulin variable heavy-chain-mutated CLL. To juxtapose proliferative with antiapoptotic signals, we investigated the effects of CpG in the context of CD40 ligation in mutated versus unmutated CLL cells in this study. Prolonged CD40 ligation induced classical, followed by alternative nuclear factor-kappaB (NF-kappaB), activity in both subgroups, correlating with enhanced Bfl-1 and Bcl-X(L) levels, respectively. A dichotomy in NF-kappaB signaling occurred on combined CD40/TLR9 triggering. This induced declining p52 and Bcl-X(L) levels, and reversed chemoresistance only in mutated cells, whereas unmutated cells proliferated, maintained p52 and Bcl-X(L) and remained chemoresistant. The pivotal contribution of Bcl-X(L) to chemoresistance was shown by the BH3 mimetic ABT-737 and RNA interference. Finally, in ex vivo LN samples, p52, p65 and Bcl-X(L) levels were highly expressed, corroborating the in vitro findings. Thus, a distinction in NF-kappaB activation and drug susceptibility in mutated versus unmutated (LN-like) CLL cells was uncovered, which was causally linked to Bcl-X(L) levels.


Subject(s)
CD40 Antigens/agonists , Drug Resistance, Neoplasm , Immunoglobulin Heavy Chains/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , NF-kappa B/physiology , Toll-Like Receptor 9/agonists , Animals , Biphenyl Compounds/pharmacology , CD40 Antigens/metabolism , CD40 Ligand/metabolism , CD40 Ligand/pharmacology , Cell Proliferation/drug effects , Cells, Cultured , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/genetics , Humans , Immunoglobulin Variable Region/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Lymphocyte Activation/drug effects , Mice , Mutation/physiology , NIH 3T3 Cells , Nitrophenols/pharmacology , Oligodeoxyribonucleotides/pharmacology , Piperazines/pharmacology , Signal Transduction/drug effects , Signal Transduction/physiology , Sulfonamides/pharmacology , Toll-Like Receptor 9/metabolism , bcl-X Protein/metabolism , bcl-X Protein/physiology
7.
Euro Surveill ; 14(16)2009 Apr 23.
Article in English | MEDLINE | ID: mdl-19389338

ABSTRACT

Two clusters of invasive meningococcal disease in the north of Italy both due to serogroup C/ST-11 clonal complex are here described. The objective of the investigation was to analyse the phenotype and the genotype of meningococci involved in the two clusters which were of national relevance due to the fatal outcome of the majority of cases (six of the total of 10 cases). All the strains were C:2a:P1.5 ST-11/ET-37 clonal complex. Two pulsed field gel electrophoresis (PFGE) and variable number tandem repeats (VNTR) profiles were identified, one for each cluster. VNTRs were different from those detected in Italy for C/ST-11 strains isolated from sporadic cases in the same period. This laboratory surveillance report highlights the importance and the crucial role of molecular characterisation to confirm the relatedness among meningococci responsible for clusters of cases.


Subject(s)
Meningitis, Meningococcal/diagnosis , Meningitis, Meningococcal/epidemiology , Neisseria meningitidis, Serogroup C/isolation & purification , Adolescent , Adult , Cluster Analysis , Humans , Italy/epidemiology , Meningitis, Meningococcal/genetics , Middle Aged , Neisseria meningitidis, Serogroup C/genetics , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...